1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsHarnessing Enzymatic Activity for Lifesaving Remedies (HEALR) is sponsored by Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO). The HEALR program seeks to develop new medical countermeasures that result in host-driven degradation or deactivation of pathogen targets to combat microbial infections, including antibiotic-resistant and multidrug-resistant pathogens.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Department of War organization. Harnessing Enzymatic Activity for Lifesaving Remedies Microbial infections are a problem of particular concern to the Department of War (DOW). The DOW has long recognized the warfighter’s outsized risk of exposure to infectious disease, including the rise of antimicrobial resistant (AMR) and multidrug resistant (MDR) pathogens that have challenged military wound care in Iraq and Afghanistan.
Furthermore, the responsibility of the DOW to protect the homeland encompasses biological threat agents, including bacterial threats, for which effective countermeasures are critical. HEALR seeks to establish an orthogonal approach to treating microbial infections by harnessing advancements in recruiting native cellular host machinery to recognize and eliminate disease-related targets.
Specifically, HEALR will develop new medical countermeasures (MCMs) that result in host-driven degradation or deactivation of pathogen targets . By harnessing innate cellular processes, approaches such as proteolysis targeting chimeras (PROTACs) and similar methods can achieve superior outcomes over existing therapies.
Tools to target microbial pathogens for protein degradation (i.e., target-binding ligand development) New protein degradation modalities to enable new pathways to protein degradation or deactivation (i.e., ‘NewTACs’) A platform that leverages these advances to permit flexible and rapid response to emerging threats Biological Technologies Office
According to the current listing, eligibility includes: Proposers must be eligible to receive U. S. government contracts. Specific eligibility details would be in the full solicitation. Confirm the full requirements in the official notice before applying.
Harnessing Enzymatic Activity for Lifesaving Remedies (HEALR) is funded by Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleDARPA BTO pre-released four FY26 SBIR/STTR topics on April 30, 2026, with proposals due June 3. Two topics — SWiFT and EXPOSITION — offer Direct-to-Phase-II awards up to $1.5M, bypassing the standard Phase I gate. Here is what each topic is actually solving, why the DP2 structure matters, and how small biotech, surgical robotics, and battlefield-medicine teams should decide whether to compete.
Read article